Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.

Mohammad AM, Al-Allawi NAS.

J Cardiovasc Pharmacol. 2018 Jun;71(6):347-351. doi: 10.1097/FJC.0000000000000577.

PMID:
29554005
2.

Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Lee CR, Sriramoju VB, Cervantes A, Howell LA, Varunok N, Madan S, Hamrick K, Polasek MJ, Lee JA, Clarke M, Cicci JD, Weck KE, Stouffer GA.

Circ Genom Precis Med. 2018 Apr;11(4):e002069. doi: 10.1161/CIRCGEN.117.002069.

3.

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network.

JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1.

4.

Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.

Mahdieh N, Rabbani A, Firouzi A, Zahedmehr A, Hoseinimoghaddam M, Saedi S, Sanati H, Basiri H, Noohi F, Rabbani B, Maleki M.

Cardiovasc Toxicol. 2018 Oct;18(5):482-491. doi: 10.1007/s12012-018-9459-x. Erratum in: Cardiovasc Toxicol. 2018 Aug 9;:.

PMID:
29777510
5.

Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.

Zhong Z, Hou J, Zhang Q, Li B, Li C, Liu Z, Yang M, Zhong W, He X, Wu H, Zhong M, Zhao P.

Eur J Clin Pharmacol. 2018 Apr;74(4):423-431. doi: 10.1007/s00228-017-2393-1. Epub 2017 Dec 14.

PMID:
29243114
6.

Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.

Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G.

JACC Cardiovasc Interv. 2013 Nov;6(11):1166-75. doi: 10.1016/j.jcin.2013.06.010.

7.

CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.

Liu T, Yin T, Li Y, Song LQ, Yu J, Si R, Zhang YM, He Y, Guo WY, Wang HC.

Coron Artery Dis. 2014 Aug;25(5):412-20. doi: 10.1097/MCA.0000000000000092.

PMID:
24608794
8.

The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention.

Ayesh BM, Al-Astal IR, Yassin MM.

Int J Clin Pharm. 2019 Feb;41(1):96-103. doi: 10.1007/s11096-018-00782-3. Epub 2019 Jan 17.

PMID:
30656556
9.

Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.

Siasos G, Oikonomou E, Vavuranakis M, Kokkou E, Mourouzis K, Tsalamandris S, Zaromitidou M, Kioufis S, Tsigkou V, Deftereos S, Stefanadis C, Tousoulis D.

Cardiology. 2017;137(2):104-113. doi: 10.1159/000457947. Epub 2017 Mar 22.

PMID:
28329746
10.

CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.

Jiang M, You JH.

Cardiovasc Drugs Ther. 2017 Feb;31(1):39-49. doi: 10.1007/s10557-016-6705-y.

PMID:
27924429
11.

Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.

Wu Y, Zhou Y, Pan Y, Zhao X, Liu L, Wang D, Wang C, Li H, Johnston SC, Meng X, Wang Y, Wang Y; CHANCE Investigators.

Pharmacogenomics J. 2018 Dec;18(6):713-720. doi: 10.1038/s41397-018-0018-4. Epub 2018 Mar 8.

PMID:
29520080
12.

Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.

Novkovic M, Matic D, Kusic-Tisma J, Antonijevic N, Radojkovic D, Rakicevic L.

Eur J Clin Pharmacol. 2018 Apr;74(4):443-451. doi: 10.1007/s00228-017-2401-5. Epub 2017 Dec 19. Erratum in: Eur J Clin Pharmacol. 2018 Feb 5;:.

PMID:
29260275
13.
14.

Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.

Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Tanaka Y, Saito S.

J Cardiol. 2016 Jul;68(1):29-36. doi: 10.1016/j.jjcc.2015.07.019. Epub 2015 Oct 29.

15.

Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.

Shen DL, Wang B, Bai J, Han Q, Liu C, Huang XH, Zhang JY.

J Cardiovasc Pharmacol. 2016 Mar;67(3):232-6. doi: 10.1097/FJC.0000000000000337.

PMID:
26727381
16.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W.

Arch Cardiovasc Dis. 2013 Oct;106(10):517-27. doi: 10.1016/j.acvd.2013.06.055. Epub 2013 Sep 27. Review.

17.

CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention.

Tang XF, Han YL, Zhang JH, Wang J, Yao Y, He C, Xu B, Gao Z, Qiao SB, Chen J, Wu Y, Chen JL, Gao RL, Yang YJ, Yuan JQ.

Thromb Res. 2016 Nov;147:108-114. doi: 10.1016/j.thromres.2016.10.008. Epub 2016 Oct 7.

PMID:
27728892
18.

CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.

Xi Z, Fang F, Wang J, AlHelal J, Zhou Y, Liu W.

Platelets. 2019;30(2):229-240. doi: 10.1080/09537104.2017.1413178. Epub 2017 Dec 19.

PMID:
29257922
20.

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS.

JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543.

Supplemental Content

Support Center